Latest Breaking News On - டைம் தொழில்நுட்பங்கள் - Page 4 : comparemela.com

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs TM), today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the sale of an aggregate of 40,000,000 shares of its common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under Nasdaq Rules. The offering is expected to close on or about February 8, 2021, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds of the offering are expected to be $100 million, prior to deducting placement agent’s fees and other offering expenses payable by TYME. TYME intends to use the net proceeds from the offering for the development of the company’s clinical and preclinical assets and for general corporate purposes, capital expe

New yorkUnited statesTyme technologies incExchange commissionExchange commission onHc wainwright coTyme technologiesPrivate securities litigation reform actInvestor relationsMedia inquiriesபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்டைம் தொழில்நுட்பங்கள் இன்க்பரிமாற்றம் தரகுபரிமாற்றம் தரகு ஆன்ஹ்ஸீ வேந்‌ரைட் இணை